Zdroje

PPTA prepares policy documents (such as issue briefs, statements, backgrounds, and white papers) on a variety of policy topics that are relevant to protecting patient access and are important to the association and its members.

Magazine of the plasma protein therapeutics industry - Winter 2011

PPTA advocates for rational regulatory policy through active dialogue with regulatory authorities throughout the world. PPTA supports regulatory policies that help ensure the safety and quality of plasma protein therapies. Regulatory staff respond to policy documents and issues, as needed, and are actively engaged on issues ranging from the collection of source plasma through the manufacture of therapies that are administered to patients. As regulations may differ in various parts of the world, PPTA also works to promote harmonization among them, where beneficial.

The CBER Surveillance Program BEST Initiative recently posted its Assessment of Immune Globulin Utilization in Commercially insured and Medicare Populations study report. The aim of the study is to provide a better picture of the evolution of Ig use over a 10-year longitudinal period in the context of emerging scientific evidence and clinical trends. PPTA developed an Executive Summary of the study report, highlighting key observations, findings, and conclusions.